Global Blood Therapeutics, Inc. Sustainability Profile
Global Blood Therapeutics, Inc. (GBT) is a pioneering biopharmaceutical company headquartered in the United States, with a focus on developing innovative treatments for sickle cell disease and other blood disorders. Founded in 2011, GBT has made significant strides in the industry, particularly with its flagship product, Oxbryta (voxelotor), which uniquely targets the underlying cause of sickle cell disease by increasing haemoglobin's affinity for oxygen. With a commitment to transforming the lives of patients, GBT has established a strong market position, recognised for its dedication to research and development in the haematology sector. The company continues to expand its operational reach, aiming to address unmet medical needs and improve patient outcomes globally. Through its innovative approach and robust pipeline, Global Blood Therapeutics is at the forefront of advancing therapies that enhance the quality of life for individuals affected by blood disorders.
DitchCarbon Score
How does Global Blood Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Global Blood Therapeutics, Inc.'s score of 84 is higher than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Global Blood Therapeutics, Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Pfizer Inc., and any climate commitments or reduction targets are inherited from its parent organisation. As part of its climate strategy, Global Blood Therapeutics aligns with initiatives set forth by Pfizer Inc., which includes participation in the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative. These initiatives aim to drive significant reductions in greenhouse gas emissions across their operations. While specific reduction targets for Global Blood Therapeutics are not detailed, the overarching commitments from Pfizer Inc. suggest a focus on sustainability and climate action. The company is expected to adhere to industry-standard climate terminology and practices, reflecting a commitment to reducing its carbon footprint in line with its parent company's goals. In summary, while specific emissions data for Global Blood Therapeutics is not available, the company is positioned within a framework of climate commitments and initiatives led by Pfizer Inc., indicating a proactive approach to addressing climate change.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | - | - | - | - | - | 000,000,000 | - | - | - | 000,000,000 |
| Scope 2 | - | - | - | - | - | - | - | - | 000,000,000 | - | - | - | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | - | 000,000,000 | 0,000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 |
How Carbon Intensive is Global Blood Therapeutics, Inc.'s Industry?
How Carbon Intensive is Global Blood Therapeutics, Inc.'s Location?
Global Blood Therapeutics, Inc.'s Scope 3 Categories Breakdown
Global Blood Therapeutics, Inc.'s Scope 3 emissions, which increased by 688% last year and increased significantly since 2019, demonstrating supply chain emissions tracking. Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 77% of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 79% of Scope 3 emissions.
Top Scope 3 Categories
Global Blood Therapeutics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Global Blood Therapeutics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
